Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 ...

Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its ...

Cynata Therapeutics completes patient enrolment in phase 2 trial of CYP-001 in adults with newly diagnosed, high risk aGvHD: Melbourne, Australia Tuesday, December 16, 2025, 14:00 ...

Cynata Therapeutics has achieved a major catalyst for 2025 by completing patient enrolment in its Phase II clinical trial of ...

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official ...

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled ...

Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...

Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...

Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its ...

“To provide menstruating patients with sickle cell disease the best care, primary care physicians, gynecologists, and ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

The US Food and Drug Administration (FDA) has granted Neurizon Therapeutics an early Christmas present by completing its ...